Format

Send to

Choose Destination
J Med Chem. 2019 Jul 11;62(13):6377-6390. doi: 10.1021/acs.jmedchem.9b00878. Epub 2019 Jun 26.

De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.

Author information

1
Davenport Research Laboratories, Department of Chemistry , University of Toronto , 80 St. George Street , Toronto , Ontario M5S 3H6 , Canada.
2
Drug Discovery Program , Ontario Institute for Cancer Research, MaRS Centre , 661 University Avenue , Suite 510 , Toronto , Ontario M5G 0A3 , Canada.
3
Princess Margaret Cancer Centre , University Health Network , 610 University Avenue , Toronto , Ontario M5G 2M9 , Canada.
4
Department of Chemical Biology and Therapeutics , St. Jude Children's Research Hospital , 262 Danny Thomas Place , Memphis , Tennessee 38105-3678 , United States.
5
Leslie Dan Faculty of Pharmacy , University of Toronto , 144 College Street , Toronto , Ontario M5S 3M2 , Canada.

Abstract

Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function. Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center